Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
← catalyst calendarNCT07100080 · readout in 849 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
500estimated
Sites
186
Countries
Argentina, Belgium, Canada +22
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-05 | actual | When the study began enrolling |
| Primary completion | 2028-12-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-11-15 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Small Cell Lung Cancer
Interventions
- Drug: Iza-bren — also filed as BMS-986507, BL-B01D1, Izalontamab brengitecan
- Drug: Carboplatin
- Drug: Cisplatin
- Drug: Pemetrexed
Primary outcomes
what the primary-completion date above is the date OFRecommended Phase 3 Dose (RP3D) of BMS-986507
measured Approximately 3 months after the first dose
Progression-Free Survival (PFS) Assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR)
measured Up to 3 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed